Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Benzinga_recent_news

Aug 27, 2025

The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562751929"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562751929\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562751929?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/26/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=120","is_english":true,"pubTime":"2025-08-27 02:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562751929","market":"us","top_or_hot":-1,"title":"Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker","media":"Benzinga_recent_news","content":"<div>\n<p>The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47342596/gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-27 02:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47342596/gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47342596/gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47342596/gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker","article_id":"2562751929","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/26/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47342596/gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2562751929","pubTimestamp":1756234380,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GYRE":"Gyre Therapeutics","CHB":"Global X China Biotech Innovation ETF"},"translate_title":"Gyre Therapeutics作为不为人知的肝纤维化药物制造商而受到关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GYRE":1,"CHB":1},"content_text":"The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical science, new therapies are emerging that promise to transform patient care and redefine market leadership in these critical areas.\nOn Tuesday, HC Wainwright initiated coverage on Gyre Therapeutics Inc. GYRE, a commercial-stage biopharmaceutical company focused on drugs for organ fibrosis.\nIts flagship product, ETUARY (pirfenidone capsule), was the first approved treatment for idiopathic pulmonary fibrosis (IPF) in China in 2011, with sales of $105 million in 2024.\nGyre Therapeutics reported second-quarter sales of $26.78 million, missing the consensus of $30.8 million.\nFor the full year 2025, the company expects to generate revenues of $118 million to $128 million, representing growth of 11.3% to 20.8% over 2024 revenue, primarily driven by the anticipated commercial launches of Etorel and Contiva and sales of ETUARY.\nGyre’s lead asset under development is hydronidone (also known as F351), which is a structural analog of the anti-fibrotic drug pirfenidone.\nAnalyst Matthew Keller writes that Hydronidone is a potent inhibitor of fibrosis that targets key molecules in the transforming growth factor beta (TGF-β) pathway, particularly in the liver.\nAlso Read: European Advisory Panel Backs Conditional Approval For Madrigal’s Fatty Liver Disease Drug\nIn May, Hydronidone met the primary endpoint in a pivotal Phase 3 trial evaluating its efficacy and safety for liver fibrosis in patients with chronic hepatitis B (CHB) in China.\nThe trial showed a statistically significant proportion of patients receiving Hydronidone achieving a ≥1-stage regression in liver fibrosis compared to placebo (P=0.0002). These results are consistent with the efficacy and safety outcomes observed in Gyre’s prior Phase 2 trial.\nThe therapy is anticipated to enter clinical Phase 2 assessment for MASH and liver fibrosis in the U.S. in the second half of 2025.\nGyre intends to seek accelerated approval for hydronidone in CHB fibrosis, with a submission of a new drug application to the Chinese regulatory authority expected in the third quarter of 2025.\nIn addition to hydronidone, the company boasts a portfolio of clinical and commercial-stage therapies for fibrosis and other related inflammatory indications.\nIn June, Gyre dosed the first volunteer in a Phase 1 trial evaluating F230, a novel endothelin A (ETA) receptor antagonist, for pulmonary arterial hypertension (PAH).\nDespite these upsides, HC Wainwright writes that “Gyre’s story is still flying under the radar with investors, its portfolio of established therapeutics is compelling, and the stock represents significant upside for investors that warrants additional attention.”\nHC Wainwright initiated with a Buy rating and a price forecast of $18.\nIn May, the company raised approximately $23 million via a public offering of 2.56 million shares of its common stock at $9.00 per share.\nIn March 2024, Madrigal Pharmaceuticals Inc.'s MDGL Rezdiffra (resmetirom) became the first FDA-approved treatment for MASH, liver scarring due to fatty liver disease.\nMadrigal anticipates strong revenue growth for Rezdiffra, potentially reaching nearly $5 billion in annual sales by 2031.\n“Although mechanistically differentiated products, we believe REZDIFFRA’s success is a window into hydronidone’s future,” the analyst wrote in an investor note.\nKeller forecasts hydronidone could also be a blockbuster drug with estimated annual sales in the U.S. of approximately $6 billion by 2033.\nMost recently, the FDA approved an additional indication for Novo Nordisk A/S' NVO Wegovy (semaglutide 2.4 mg) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity.\nGYRE Price Action: Gyre Therapeutics shares were down 6.04% at $7.70 at the time of publication on Tuesday, according to Benzinga Pro data.\nRead Next:\nPhoto: jittawit21/Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}